BioCentury | Aug 24, 2015
Clinical News

AVN-211: Phase IIb data

...patients with mild to moderate Alzheimer’s disease (AD). Avineuro has rights to AVN-211 from AllaChem. AllaChem LLC...
BioCentury | Jan 5, 2015
Clinical News

AV4025: Phase Ib data

...reported. Additionally, high-dose AV-4025 led to a median 3.35 log reduction in HCV RNA levels. AllaChem LLC...
BioCentury | Jun 2, 2014
Clinical News

AVR560: Phase Ib started

...evaluate once-daily 100 and 150 mg oral AVR560 for 14 days in treatment-naïve HCV patients. AllaChem LLC...
BioCentury | May 26, 2014
Clinical News

ONC1-13B: Phase I started

...240 and 320 mg ONC1-13B for up to 72 weeks in up to 40 patients. AllaChem LLC...
BioCentury | May 19, 2014
Clinical News

AV4025: Phase Ib started

...oral AV4025 once daily for 3 days in about 20 treatment-naïve patients with HCV infection. AllaChem LLC...
BioCentury | Oct 21, 2013
Clinical News

AV4025: Phase I data

...presented at the Viral Hepatitis: Epidemiology, Diagnostics, Treatment and Prophylaxis meeting in Moscow. In 1Q14, AllaChem...
BioCentury | Sep 2, 2013
Clinical News

Alla Chem preclinical data

...a lower potential for drug-drug interactions vs. Xtandi enzalutamide (formerly MDV3100 ) and ARN-509 . Alla Chem...
...CRPC. Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) is acquiring Aragon (see BioCentury, June 24). Alla Chem...
BioCentury | Aug 19, 2013
Clinical News

AV4025: Phase I started

...HCV infection Endpoint: Safety and pharmacokinetics Status: Phase I started Milestone: Phase I data (09/2013) Alla Chem...
Items per page:
1 - 8 of 8
BioCentury | Aug 24, 2015
Clinical News

AVN-211: Phase IIb data

...patients with mild to moderate Alzheimer’s disease (AD). Avineuro has rights to AVN-211 from AllaChem. AllaChem LLC...
BioCentury | Jan 5, 2015
Clinical News

AV4025: Phase Ib data

...reported. Additionally, high-dose AV-4025 led to a median 3.35 log reduction in HCV RNA levels. AllaChem LLC...
BioCentury | Jun 2, 2014
Clinical News

AVR560: Phase Ib started

...evaluate once-daily 100 and 150 mg oral AVR560 for 14 days in treatment-naïve HCV patients. AllaChem LLC...
BioCentury | May 26, 2014
Clinical News

ONC1-13B: Phase I started

...240 and 320 mg ONC1-13B for up to 72 weeks in up to 40 patients. AllaChem LLC...
BioCentury | May 19, 2014
Clinical News

AV4025: Phase Ib started

...oral AV4025 once daily for 3 days in about 20 treatment-naïve patients with HCV infection. AllaChem LLC...
BioCentury | Oct 21, 2013
Clinical News

AV4025: Phase I data

...presented at the Viral Hepatitis: Epidemiology, Diagnostics, Treatment and Prophylaxis meeting in Moscow. In 1Q14, AllaChem...
BioCentury | Sep 2, 2013
Clinical News

Alla Chem preclinical data

...a lower potential for drug-drug interactions vs. Xtandi enzalutamide (formerly MDV3100 ) and ARN-509 . Alla Chem...
...CRPC. Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) is acquiring Aragon (see BioCentury, June 24). Alla Chem...
BioCentury | Aug 19, 2013
Clinical News

AV4025: Phase I started

...HCV infection Endpoint: Safety and pharmacokinetics Status: Phase I started Milestone: Phase I data (09/2013) Alla Chem...
Items per page:
1 - 8 of 8